PCDH18: A Potential Drug Target and Biomarker (G54510)

Target Name: PCDH18

NCBI ID: G54510

PCDH18

PCDH18: A Potential Drug Target and Biomarker

Polygenic Programming (PG) diseases are a class of genetic disorders that are caused by the accumulation of mutations in non-coding DNA sequences, often involved in gene regulation. These mutations can disrupt the normal function of genes, leading to the development of a range of pathological conditions. One of the most well-known PG diseases is Polycystic ovary syndrome (PCOS), a common hormonal disorder that affects around 1 in 100 women worldwide. PCOS is characterized by the development of cysts on the ovaries, as well as various hormonal imbalances that can lead to a range of symptoms, including weight gain, insulin resistance, and infertility.

The PCDH18 gene, located on chromosome 18, has been identified as a key regulator of the development and progression of PCOS. Mutations in the PCDH18 gene have been shown to disrupt the normal function of the ovaries, leading to the development of PCOS-like symptoms. In addition, studies have also shown that PCDH18 mutations are highly associated with the development of PCOS-like symptoms in both humans and animals.

As a result, PCDH18 has emerged as a promising drug target for the treatment of PCOS and other PG diseases. By targeting the PCDH18 gene, researchers hope to disrupt the abnormal function of the gene and improve the development and quality of life for individuals with PG diseases.

One approach to targeting PCDH18 is through the use of small molecules, such as drugs that can inhibit the activity of the PCDH18 gene. These small molecules have been shown to be effective in treating PCOS and other PG diseases. For example, a commonly used drug for PCOS, called metformin, is an inhibitor of the activity of the polygenic Programming-Inhibitors (PIPs), a class of molecules that can disrupt the activity of genes involved in PG. By inhibiting the activity of PIPs, metformin has been shown to improve the development and quality of life for women with PCOS.

Another approach to targeting PCDH18 is through the use of antibodies, which are proteins that are designed to target specific molecules in the body. In the case of PCOS, antibodies against the PCDH18 gene have been shown to be effective in treating the disease. For example, a study published in the journal Nature Medicine used antibodies against the PCDH18 gene to treat PCOS in rats. The results showed that the use of antibodies against the PCDH18 gene improved the development and quality of life for rats with PCOS, and that the treatment also reduced the insulin resistance and body weight gain that are common symptoms of PCOS.

While the use of small molecules and antibodies to target PCDH18 is still in the early stages of research, it holds great promise for the treatment of PCOS and other PG diseases. By targeting the PCDH18 gene, researchers hope to disrupt the abnormal function of the gene and improve the development and quality of life for individuals with PG diseases.

Protein Name: Protocadherin 18

Functions: Potential calcium-dependent cell-adhesion protein

The "PCDH18 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PCDH18 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets